Industry Verticals »

All Categories

Insights »

About TMR »

Hospital acquired disease testing Market

Hospital acquired disease testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • According to Transparency Market Research’s latest report on the global hospital acquired disease testing market for the historical period 2017–2018 and forecast period 2019–2027, Increase in prevalence of hospital acquired infections and rise in the number of drug resistant pathogens and Establishment of government guidelines and code for prevention of hospital acquired infections are projected to drive the global hospital acquired disease testing market during the forecast period
  • According to the report, the global hospital acquired disease testing market was valued at US$ 798.6 Mn in 2018 and is anticipated to expand at a CAGR of 14.7% from 2019 to 2027

To know the scope of our report Get a Sample on Hospital Acquired Disease Testing Market

Rise in the Number of Drug Resistant Pathogens: Key Drivers

  • Rapid and efficient solutions for infection detection not only assist in controlling the incidence of nosocomial infections, but also in controlling the overall medical costs, hospital stays, and death.
  • Widespread availability of more sophisticated infection detection solutions particularly those under molecular diagnostics and their proven efficiency in delivering faster results has led to rise in demand for such products across the world.
  • Government initiatives and hospital acquired infection controlling authorities focusing on spreading awareness about hospital acquired infection and available treatments are driving demand for hospital acquired infection testing.
  • Therefore, increase in prevalence of hospital acquired infections and rise in drug resistant pathogens are fueling the growth of the hospital acquired infection testing market.

Get a glimpse of the in-depth analysis through our Report Brochure

Establishment of Government Guidelines and Code for Prevention of hospital acquired infections to Boost Market Growth

  • According to the U.S. Department of Health and Human Services, hospital acquired infection prevention costs around US$ 28.0 Bn to US$ 33.0 Bn annually. In order to reduce the burden on hospitals resulting from extended stay of patients in hospitals, governments are taking initiatives to reduce hospital acquired infection prevalence in the respective countries.
  • Developed countries have hospital acquired infection prevention and control authorities, with established guidelines for detection and treatment of hospital acquired infection. For example, the Centers for Disease Control and Prevention (CDC) recommends nucleic acid amplification test for detection of C. difficile, while the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends two-step detection process for identification of C. difficile.
  • These guidelines drive the market for recommended tests in countries where the regulatory and guiding frameworks are established and followed. Therefore, stringent government regulations would boost the growth of the global hospital acquired infection testing market.

Expanding operations in future? To get the perfect launch ask for a custom report 

Stringent Regulations and Guidance Framework to Hamper Market

  • One of the major key constraints for successful adoption of molecular biology based diagnostics involves government regulations. All the major geographical markets have their own form of regulatory regime that covers the diagnostics domain.
  • Such systems have been created long back and were not designed for the specific intention of regulating molecular biology based diagnostics.
  • Moreover, the time and capital required to design and develop these products discourage manufacturers to engage in the development of novel and innovative products that could be introduced in various markets. Thus, stringent regulations are likely to restrain market growth during the forecast period.

Global Hospital acquired disease testing Market: Competitive Landscape

  • This report profiles major players in the global hospital acquired disease testing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.
  • The hospital acquired disease testing market is highly fragmented with a number of international and local players operating in the market. The companies profiled in the report include
    • Abbott Laboratories
    • Alere, Inc.,
    • Becton
    • Dickinson and Company
    • bioMérieux SA, F
    • Hoffmann-La Roche Ltd
    • Hologic, Inc
    •  Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.,
    • Thermo Fisher Scientific, Inc.

Global Hospital acquired disease testing Market: Key Developments

  • In January 2015, bioMérieux acquired the CEERAM (European Centre for Expertise and Research on Microbial Agents), an innovative molecular virology laboratory that specializes in the detection of foodborne and environmental viruses.

The report on the global hospital acquired disease testing market discussed individual strategies, followed by company profile of manufacturer of hospital acquired disease testing. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hospital acquired disease testing market.

Global Hospital acquired disease testing Market – Segmentation

Test Type

Urinary Tract

Surgical Site

Pneumonia

Bloodstream

MRSA

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of hospital acquired disease testing market?

Hospital acquired disease testing market to reach US$ 2.85 Bn by 2027

What is the anticipated CAGR of the hospital acquired disease testing market in the forecast period?

Hospital acquired disease testing market to expand at a CAGR of 14.7% from 2019 to 2027

What are the key driving factors for the growth of the hospital acquired disease testing market?

Hospital acquired disease testing market is driven by increase in prevalence of hospital acquired infections and rise in the number of drug resistant pathogens

Which region is expected to project the highest market share in the global hospital acquired disease testing market?

North America accounted for a major share of the global hospital acquired disease testing market

Who are the key players in the hospital acquired disease testing market?

Key players in the global hospital acquired disease testing market include Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Hospital Acquired Disease Testing Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Hospital Acquired Disease Testing Market Analysis and Forecasts, 2017–2027

        4.5. Porter’s Five Force Analysis

    5. Key Insights

        5.1. Disease Prevalence & Incidence Rate globally with key countries

        5.2. Technological Advancements

    6. Global Hospital Acquired Disease Testing Market Analysis and Forecasts, By Test Type 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Test Type, 2017–2027

            6.3.1. Urinary Tract Infection

            6.3.2. Surgical Site

            6.3.3. Pneumonia

            6.3.4. Bloodstream

            6.3.5. MRSA

            6.3.6. Others 

        6.4. Market Attractiveness By Test Type 

    7. Global Hospital Acquired Disease Testing Market Analysis and Forecasts, By Region

        7.1. Key Findings

        7.2. Market Value Forecast By Region

            7.2.1. North America 

            7.2.2. Europe 

            7.2.3. Asia Pacific 

            7.2.4. Latin America 

            7.2.5. Middle East & Africa 

        7.3. Market Attractiveness By Region

    8. North America Hospital Acquired Disease Testing Market Analysis and Forecast

        8.1. Introduction

        8.2. Market Value Forecast By Test Type, 2017–2027

            8.2.1. Urinary Tract Infection

            8.2.2. Surgical Site

            8.2.3. Pneumonia

            8.2.4. Bloodstream

            8.2.5. MRSA

            8.2.6. Others 

        8.3. Market Value Forecast By Country, 2017–2027

            8.3.1. U.S.

            8.3.2. Canada

        8.4. Market Attractiveness Analysis 

            8.4.1. By Test Type 

            8.4.2. By Country

    9. Europe Hospital Acquired Disease Testing Market Analysis and Forecast

        9.1. Introduction

        9.2. Market Value Forecast By Test Type, 2017–2027

            9.2.1. Urinary Tract Infection

            9.2.2. Surgical Site

            9.2.3. Pneumonia

            9.2.4. Bloodstream

            9.2.5. MRSA

            9.2.6. Others 

        9.3. Market Value Forecast By Country, 2017–2027

            9.3.1. Germany

            9.3.2. U.K.

            9.3.3. France

            9.3.4. Spain

            9.3.5. Italy

            9.3.6. Rest of Europe

        9.4. Market Attractiveness Analysis 

            9.4.1. By Test Type 

            9.4.2. By Country

    10. Asia Pacific Hospital Acquired Disease Testing Market Analysis and Forecast

        10.1. Introduction

        10.2. Market Value Forecast By Test Type, 2017–2027

            10.2.1. Urinary Tract Infection

            10.2.2. Surgical Site

            10.2.3. Pneumonia

            10.2.4. Bloodstream

            10.2.5. MRSA

            10.2.6. Others 

        10.3. Market Value Forecast By Country, 2017–2027

            10.3.1. China

            10.3.2. Japan

            10.3.3. India

            10.3.4. Australia & New Zealand

            10.3.5. Rest of Asia Pacific

        10.4. Market Attractiveness Analysis 

            10.4.1. By Test Type 

            10.4.2. By Country

    11. Latin America Hospital Acquired Disease Testing Market Analysis and Forecast

        11.1. Introduction

        11.2. Market Value Forecast By Test Type, 2017–2027

            11.2.1. Urinary Tract Infection

            11.2.2. Surgical Site

            11.2.3. Pneumonia

            11.2.4. Bloodstream

            11.2.5. MRSA

            11.2.6. Others 

        11.3. Market Value Forecast By Country, 2017–2027

            11.3.1. Brazil

            11.3.2. Mexico

            11.3.3. Rest of Latin America

        11.4. Market Attractiveness Analysis 

            11.4.1. By Test Type 

            11.4.2. By Country

    12. Middle East & Africa Hospital Acquired Disease Testing Market Analysis and Forecast

        12.1. Introduction

        12.2. Market Value Forecast By Test Type, 2017–2027

            12.2.1. Urinary Tract Infection

            12.2.2. Surgical Site

            12.2.3. Pneumonia

            12.2.4. Bloodstream

            12.2.5. MRSA

            12.2.6. Others 

        12.3. Market Value Forecast By Country, 2017–2027

            12.3.1. GCC Countries

            12.3.2. South Africa

            12.3.3. Rest of Middle East & Africa

        12.4. Market Attractiveness Analysis 

            12.4.1. By Test Type 

            12.4.2. By Country

    13. Competition Landscape

        13.1. Abbott Laboratories

            13.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.2. Financial Overview

            13.1.3. Growth Strategies

            13.1.4. SWOT Analysis

        13.2. Becton, Dickinson and Company

            13.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.2.2. Financial Overview

            13.2.3. Growth Strategies

            13.2.4. SWOT Analysis

        13.3. bioMérieux SA

            13.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.2. Financial Overview

            13.3.3. Growth Strategies

            13.3.4. SWOT Analysis

        13.4. F. Hoffmann-La Roche Ltd.

            13.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.4.2. Financial Overview

            13.4.3. Growth Strategies

            13.4.4. SWOT Analysis

        13.5. Hologic, Inc.

            13.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.5.2. Financial Overview

            13.5.3. Growth Strategies

            13.5.4. SWOT Analysis

        13.6. Siemens Healthcare

            13.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.6.2. Financial Overview

            13.6.3. Growth Strategies

            13.6.4. SWOT Analysis

        13.7. Diatherix Laboratories, Inc.

            13.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.7.2. Financial Overview

            13.7.3. Growth Strategies

            13.7.4. SWOT Analysis

        13.8. Meridian Bioscience, Inc.

            13.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.8.2. Financial Overview

            13.8.3. Growth Strategies

            13.8.4. SWOT Analysis

        13.9. Thermo Fisher Scientific, Inc.

            13.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.9.2. Financial Overview

            13.9.3. Growth Strategies

            13.9.4. SWOT Analysis

    List of Table

    Table 01 Hospital Acquired Disease Testing Market Size (US$ Mn) Forecast, By Test Type, 2019–2027

    Table 02 Hospital Acquired Disease Testing Market Size (US$ Mn) Forecast, By Geography, 2019–2027

    Table 03 North America Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Test Type ,2019–2027

    Table 04 North America Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Country ,2019–2027

    Table 05 Europe Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Test Type ,2019–2027

    Table 06 Europe Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Country, 2019–2027

    Table 07 Asia Pacific Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Test Type ,2019–2027

    Table 08 Asia Pacific Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Country ,2019–2027

    Table 09 Latin America Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Test Type ,2019–2027

    Table 10 Latin America Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Country ,2019–2027

    Table 11 Middle East & Africa Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Test Type ,2019–2027

    Table 12 Middle East & Africa Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, By Country ,2019–2027

    List of Figure

    Figure 01 Hospital Acquired Disease Testing Market Snapshot

    Figure 02 Hospital Acquired Disease Testing Market Size (US$ Mn) And Forecast, 2019–2027

    Figure 03 Hospital Acquired Disease Testing Market Attractiveness Analysis By Test Type

    Figure 04 Hospital Acquired Disease Testing Market Revenue (US$ Mn) And Y-O-Y Growth (%), North America, 2019–2027

    Figure 05 Hospital Acquired Disease Testing Market Revenue (US$ Mn) And Y-O-Y Growth (%),Europe, 2019–2027

    Figure 06 Hospital Acquired Disease Testing Market Revenue (US$ Mn) And Y-O-Y Growth (%),Asia Pacific, 2019–2027

    Figure 07 Hospital Acquired Disease Testing Market Revenue (US$ Mn) And Y-O-Y Growth (%),Latin America, 2019–2027

    Figure 08 Hospital Acquired Disease Testing Market Revenue (US$ Mn) And Y-O-Y Growth (%),Middle East & Africa, 2019–2027

    Figure 09 North America Hospital Acquired Disease Testing Value Share Analysis, By Test Type, 2019 And 2027

    Figure 10 North America Hospital Acquired Disease Testing Value Share Analysis, By Country, 2019 And 2027

    Figure 11 Europe Hospital Acquired Disease Testing Value Share Analysis, By Test Type, 2019 And 2027

    Figure 12 Europe Hospital Acquired Disease Testing Value Share Analysis, By Country, 2019 And 2027

    Figure 13 Asia Pacific Hospital Acquired Disease Testing Value Share Analysis, By Test Type, 2019 And 2027

    Figure 14 Asia Pacific Hospital Acquired Disease Testing Value Share Analysis, By Country, 2019 And 2027

    Figure 15 Latin America Hospital Acquired Disease Testing Value Share Analysis, By Test Type, 2019 And 2027

    Figure 16 Latin America Hospital Acquired Disease Testing Value Share Analysis, By Country, 2019 And 2027

    Figure 17 Middle East & Africa Hospital Acquired Disease Testing Value Share Analysis, By Test Type, 2019 And 2027

    Figure 18 Middle East & Africa Hospital Acquired Disease Testing Value Share Analysis, By Country, 2019 And 2027

Copyright © Transparency Market Research, Inc. All Rights reserved

Hospital acquired disease testing Market

Schedule a Call